KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Share-based Compensation (2016 - 2025)

Novavax (NVAX) has 16 years of Share-based Compensation data on record, last reported at $8.0 million in Q4 2025.

  • For Q4 2025, Share-based Compensation fell 23.75% year-over-year to $8.0 million; the TTM value through Dec 2025 reached $36.0 million, down 25.21%, while the annual FY2025 figure was $36.0 million, 25.21% down from the prior year.
  • Share-based Compensation reached $8.0 million in Q4 2025 per NVAX's latest filing, down from $8.5 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $53.1 million in Q2 2021 and bottomed at $8.0 million in Q4 2025.
  • Average Share-based Compensation over 5 years is $24.2 million, with a median of $20.5 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: soared 1238.21% in 2021, then crashed 59.66% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $32.2 million in 2021, then fell by 13.66% to $27.8 million in 2022, then crashed by 43.63% to $15.7 million in 2023, then tumbled by 33.27% to $10.4 million in 2024, then decreased by 23.75% to $8.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $8.0 million in Q4 2025, $8.5 million in Q3 2025, and $9.2 million in Q2 2025.